Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2025	Mar. 31, 2024	Mar. 31, 2025	Mar. 31, 2024
Income Statement [Abstract]
Revenue	$ 15,000,000		$ 15,662,715
Operating expenses:
Research and development	1,616,011	$ 1,198,546	5,253,953	$ 6,321,691
General and administrative	1,406,796	1,195,485	5,702,807	6,092,809
Total operating expenses	3,022,807	2,394,031	10,956,760	12,414,500
Income (loss) from operations	11,977,193	(2,394,031)	4,705,955	(12,414,500)
Other income (loss):
Interest income, net	12,741	52,615	79,452	193,770
Gain (loss) on foreign currency transactions	172,946	216,847	522,410	(148,296)
Research and development incentive award	(5,227)	271	301,006	94,981
Gain (loss) on fair value adjustments	(976,678)	(637,467)	2,703,438	(584,299)
Total other income (loss)	(796,218)	(367,734)	3,606,306	(443,844)
Income (loss) before income tax expense	11,180,975	(2,761,765)	8,312,261	(12,858,344)
Income tax benefit (expense)	81,186	(16,383)	201,764	53,204
Net Income (loss)	11,262,161	(2,778,148)	8,514,025	(12,805,140)
Other comprehensive loss:
Unrealized loss on foreign currency translation	(195,818)	(561,948)	(898,870)	(174,332)
Total other comprehensive loss:	(195,818)	(561,948)	(898,870)	(174,332)
Comprehensive income (loss)	$ 11,066,343	$ (3,340,096)	$ 7,615,155	$ (12,979,472)
Net income (loss) per share - basic	$ 6.55	$ (2.83)	$ 5.56	$ (15.2)
Weighted-average common shares outstanding - basic	1,719,073	981,040	1,530,091	842,431
Net income (loss) per share - diluted	$ 6.55	$ (2.83)	$ 3.75	$ (15.2)
Weighted-average common shares outstanding - diluted	1,719,073	981,040	1,530,091	842,431